120017
论文已发表
注册即可获取德孚的最新动态
IF 收录期刊
- 3.6 Breast Cancer (Dove Med Press)
- 4.3 Clin Epidemiol
- 2.6 Cancer Manag Res
- 3.2 Infect Drug Resist
- 4.1 Clin Interv Aging
- 6.1 Drug Des Dev Ther
- 4.1 Int J Chronic Obstr
- 8.7 Int J Nanomed
- 2.5 Int J Women's Health
- 3.2 Neuropsych Dis Treat
- 2.4 OncoTargets Ther
- 2.6 Patient Prefer Adher
- 2.6 Ther Clin Risk Manag
- 3.1 J Pain Res
- 3.5 Diabet Metab Synd Ob
- 4.5 Psychol Res Behav Ma
- 3.4 Nat Sci Sleep
- 2.4 Pharmgenomics Pers Med
- 2.6 Risk Manag Healthc Policy
- 4.6 J Inflamm Res
- 2.3 Int J Gen Med
- 3.9 J Hepatocell Carcinoma
- 3.3 J Asthma Allergy
- 2.5 Clin Cosmet Investig Dermatol
- 3.0 J Multidiscip Healthc
已发表论文
左卡尼汀联合前列地尔治疗对终末期糖尿病肾病患者肾功能、氧化-抗氧化平衡和全身炎症指标的临床疗效
Authors Cheng L, Wan S, Min Y, Tu C, Mao D, Wang Q, Fu S, Xiong F
Received 10 August 2025
Accepted for publication 28 December 2025
Published 3 February 2026 Volume 2026:22 553649
DOI https://doi.org/10.2147/TCRM.S553649
Checked for plagiarism Yes
Review by Single anonymous peer review
Peer reviewer comments 2
Editor who approved publication: Professor Garry Walsh
Li Cheng,* Sheng Wan,* Yonglong Min, Can Tu, Dongdong Mao, Quan Wang, Shuai Fu, Fei Xiong
Department of Nephrology, Wuhan No.1 Hospital, Wuhan, 430022, People’s Republic of China
*These authors contributed equally to this work
Correspondence: Fei Xiong, Email fk5431@yeah.net
Objective: To investigate the effects of combined Levocarnitine and Alprostadil therapy on renal function, oxidant-antioxidant balance, and systemic inflammation in patients with end-stage diabetic nephropathy (ESDN).
Methods: This retrospective study included 104 ESDN patients admitted to our hospital between April 2021 and April 2023 who met all inclusion criteria. All patients were on maintenance hemodialysis for chronic kidney failure due to ESDN. Based on the treatment regimen received, patients were divided into two groups: the control (n=51) received intravenous Alprostadil (20 μg/day) for 30 days in addition to standard care, and the observation group (n=53) received additional intravenous Levocarnitine (1.0 g/day) for 30 days. Clinical efficacy, renal function parameters [blood urea nitrogen (BUN), cystatin C (Cys-C), 24-hour urinary protein (24 h Upro)], oxidative stress markers [malondialdehyde (MDA), superoxide dismutase (SOD), reactive oxygen species (ROS)], inflammatory factors [C-reactive protein (CRP), interleukin-1β (IL-1β), interleukin-6 (IL-6)], and adverse reactions were compared between groups.
Results: The cumulative treatment effectiveness (defined as the sum of patients with “markedly effective” and “effective” outcomes) was significantly higher in the observation group (92.45%) compared to the control group (78.43%, P< 0.05). Post-treatment, the observation group demonstrated significantly greater improvements in all parameters: lower BUN (4.35± 1.06 vs 5.29± 1.12 mmol/L), Cys-C (1.21± 0.34 vs 1.75± 0.46 mg/L), 24 h Upro (66.79± 18.37 vs 75.17± 19.54 mg/24h), MDA (3.54± 0.89 vs 4.63± 1.08 nmol/mL), ROS (371.34± 46.32 vs 417.53± 48.16 U/mL), CRP (5.02± 0.83 vs 6.63± 0.94 mg/L), IL-1β (11.04± 2.38 vs 13.61± 2.67 pg/mL), and IL-6 (12.78± 3.51 vs 16.84± 4.53 pg/mL), alongside higher SOD (88.17± 9.34 vs 72.49± 8.71 U/mL) (P< 0.05). Adverse reaction incidence showed no significant difference (16.98% vs 13.73%, P> 0.05).
Conclusion: In ESDN patients, the combination of Levocarnitine and Alprostadil demonstrates superior cumulative treatment effectiveness over Alprostadil monotherapy in improving renal function, reducing oxidative stress, and attenuating inflammation, without increasing the incidence of adverse reactions.
Keywords: end-stage diabetic nephropathy, levocarnitine, alprostadil, renal function, oxidative stress, inflammatory response
Department of Nephrology, Wuhan No.1 Hospital, Wuhan, 430022, People’s Republic of China
*These authors contributed equally to this work
Correspondence: Fei Xiong, Email fk5431@yeah.net
Objective: To investigate the effects of combined Levocarnitine and Alprostadil therapy on renal function, oxidant-antioxidant balance, and systemic inflammation in patients with end-stage diabetic nephropathy (ESDN).
Methods: This retrospective study included 104 ESDN patients admitted to our hospital between April 2021 and April 2023 who met all inclusion criteria. All patients were on maintenance hemodialysis for chronic kidney failure due to ESDN. Based on the treatment regimen received, patients were divided into two groups: the control (n=51) received intravenous Alprostadil (20 μg/day) for 30 days in addition to standard care, and the observation group (n=53) received additional intravenous Levocarnitine (1.0 g/day) for 30 days. Clinical efficacy, renal function parameters [blood urea nitrogen (BUN), cystatin C (Cys-C), 24-hour urinary protein (24 h Upro)], oxidative stress markers [malondialdehyde (MDA), superoxide dismutase (SOD), reactive oxygen species (ROS)], inflammatory factors [C-reactive protein (CRP), interleukin-1β (IL-1β), interleukin-6 (IL-6)], and adverse reactions were compared between groups.
Results: The cumulative treatment effectiveness (defined as the sum of patients with “markedly effective” and “effective” outcomes) was significantly higher in the observation group (92.45%) compared to the control group (78.43%, P< 0.05). Post-treatment, the observation group demonstrated significantly greater improvements in all parameters: lower BUN (4.35± 1.06 vs 5.29± 1.12 mmol/L), Cys-C (1.21± 0.34 vs 1.75± 0.46 mg/L), 24 h Upro (66.79± 18.37 vs 75.17± 19.54 mg/24h), MDA (3.54± 0.89 vs 4.63± 1.08 nmol/mL), ROS (371.34± 46.32 vs 417.53± 48.16 U/mL), CRP (5.02± 0.83 vs 6.63± 0.94 mg/L), IL-1β (11.04± 2.38 vs 13.61± 2.67 pg/mL), and IL-6 (12.78± 3.51 vs 16.84± 4.53 pg/mL), alongside higher SOD (88.17± 9.34 vs 72.49± 8.71 U/mL) (P< 0.05). Adverse reaction incidence showed no significant difference (16.98% vs 13.73%, P> 0.05).
Conclusion: In ESDN patients, the combination of Levocarnitine and Alprostadil demonstrates superior cumulative treatment effectiveness over Alprostadil monotherapy in improving renal function, reducing oxidative stress, and attenuating inflammation, without increasing the incidence of adverse reactions.
Keywords: end-stage diabetic nephropathy, levocarnitine, alprostadil, renal function, oxidative stress, inflammatory response